News | May 30, 2023
NATCO records FY23 PAT at Rs. 715.3 Cr
The increase in revenue and profits for the year was driven by business growth in the US market and growth in our subsidiaries in Canada & Brazil.
The increase in revenue and profits for the year was driven by business growth in the US market and growth in our subsidiaries in Canada & Brazil.
Operating EBITDA increased by 21% to INR 181 crores in Q4 FY23
With digitally available health records, individuals can avail paper-less health services under Ayushman Bharat Digital Mission (ABDM)
Profit after Tax stood at Rs. 106 crore as compared to Rs. 84 crore registering growth of 26%
This digital linking of individual’s health records with ABHA is being carried out extensively across different health facilities of the country
In fact, the overall CPHI Pharma Index – a collateralised metric of all major ranking categories – has risen by more than 8%, the largest year-on-year gain in the survey’s six year history
Profit after Tax stood at Rs. 105 crore as compared to Rs. 119 crore on account of higher treasury income in Q1 FY22, non-cash ESOP cost, depreciation on account of acquired brands and finance costs in Q1 FY23
The 562,000 square feet facility has been recognized as the first and largest integrated insulin manufacturer in Malaysia by MBR
The facility is designed with advanced analytical equipment to provide testing services such as In-vitro Permeation testing
India imported medical devices worth Rs. 63,200 crore in 2021-22, up 41% from Rs. 44,708 crore in 2020-21
Subscribe To Our Newsletter & Stay Updated
